Bank Of America Corp Aligos Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 816,029 shares of ALGS stock, worth $7.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

816,029

Previous 1,147,727 28.9%

Holding current value

$7.81 Million

Previous $1.12 Million 74.64%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.35 - $1.07 $116,094 - $354,916	-331,698 Reduced 28.9%	816,029 $285,000
Q1 2024 May 15, 2024	SELL	$0.64 - $1.13 $22 - $39	-35 Reduced -0.0%	1,147,727 $1.12 Million
Q4 2023 Feb 14, 2024	SELL	$0.56 - $0.8 $1,782 - $2,546	-3,183 Reduced 0.28%	1,147,762 $757,000
Q2 2023 Aug 14, 2023	BUY	$0.89 - $1.36 $2,814 - $4,300	3,162 Added 0.28%	1,150,945 $1.12 Million
Q1 2023 May 12, 2023	SELL	$0.87 - $2.11 $2,057 - $4,990	-2,365 Reduced 0.21%	1,147,783 $998,000
Q4 2022 Feb 10, 2023	BUY	$0.89 - $28.0 $1,785 - $56,168	2,006 Added 0.17%	1,150,148 $1.09 Million
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $10,993 - $285,202	10,371 Added 0.91%	1,148,142 $1.26 Million
Q2 2022 Aug 12, 2022	SELL	$1.04 - $2.14 $48,346 - $99,482	-46,487 Reduced 3.93%	1,137,771 $1.38 Million
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $41,512 - $243,487	19,958 Added 1.71%	1,184,258 $2.55 Million
Q4 2021 Feb 08, 2022	BUY	$11.48 - $17.69 $13 Million - $20 Million	1,130,571 Added 3351.93%	1,164,300 $13.8 Million
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $247,471 - $300,974	16,985 Added 101.44%	33,729 $522,000
Q2 2021 Sep 13, 2021	BUY	$20.3 - $33.6 $339,903 - $562,598	16,744 New	16,744 $341,000

Others Institutions Holding ALGS

# of Institutions

Shares Held

47.2M

Call Options Held

1.4K

Put Options Held

300

View Full List

About Aligos Therapeutics, Inc.

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $380M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

More about ALGS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Aligos Therapeutics, Inc. Transaction History